Connect Biopharma Holdings Ltd
NASDAQ:CNTB

Watchlist Manager
Connect Biopharma Holdings Ltd Logo
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Watchlist
Price: 0.9509 USD -4.19% Market Closed
Market Cap: 52.5m USD
Have any thoughts about
Connect Biopharma Holdings Ltd?
Write Note

Connect Biopharma Holdings Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Connect Biopharma Holdings Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Income from Continuing Operations
-ÂĄ59.5m
CAGR 3-Years
58%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Income from Continuing Operations
-ÂĄ6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Income from Continuing Operations
-ÂĄ1.3B
CAGR 3-Years
3%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Income from Continuing Operations
ÂĄ1.2B
CAGR 3-Years
22%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Income from Continuing Operations
ÂĄ3.7B
CAGR 3-Years
-26%
CAGR 5-Years
12%
CAGR 10-Years
39%
Imeik Technology Development Co Ltd
SZSE:300896
Income from Continuing Operations
ÂĄ1.9B
CAGR 3-Years
62%
CAGR 5-Years
74%
CAGR 10-Years
N/A
No Stocks Found

Connect Biopharma Holdings Ltd
Glance View

Market Cap
52.5m USD
Industry
Biotechnology

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.

CNTB Intrinsic Value
0.3275 USD
Overvaluation 66%
Intrinsic Value
Price

See Also

What is Connect Biopharma Holdings Ltd's Income from Continuing Operations?
Income from Continuing Operations
-59.5m CNY

Based on the financial report for Dec 31, 2023, Connect Biopharma Holdings Ltd's Income from Continuing Operations amounts to -59.5m CNY.

What is Connect Biopharma Holdings Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
9%

Over the last year, the Income from Continuing Operations growth was 93%. The average annual Income from Continuing Operations growth rates for Connect Biopharma Holdings Ltd have been 58% over the past three years , 9% over the past five years .

Back to Top